Less Is More: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME (CME Monograph)

Activity Description and Purpose

This educational activity will provide clinicians with insights on the most relevant clinical data for treating wet age-related macular degeneration and diabetic retinopathy/diabetic macular edema. Experts in the field will discuss ways to extend the treatment interval and individualize care in patients who suffer from these sight-threatening diseases. The desired results of this activity are to help clinicians optimize patient care by giving them information that helps them understand the place in therapy of novel and new agents that may decrease treatment burden through extending the treatment interval.

Target Audience

This educational activity is intended for retina specialists and other ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Describe the latest clinical data for anti-VEGF treatments for wet age-related macular degeneration
  • Describe the latest clinical data for anti-VEGF treatments for diabetic retinopathy/diabetic macular edema
  • Individualize care to effectively extend the treatment interval in patients with wet age-related macular degeneration
  • Individualize care to effectively extend the treatment interval in patients with diabetic retinopathy/diabetic macular edema
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Participation
Course opens: 
Course expires: 


Katherine Talcott, MD (Chair)
Cole Eye Institute
Cleveland Clinic
Cleveland, Ohio

Zelia M. Correa, MD, PhD
Professor of Ophthalmology
Director, Ocular Oncology and Echography Services
Bascom Palmer Eye Institute
Miami, Florida


Jessica Randolph, MD, FASRS
Assistant Professor of Ophthalmology
Virginia Commonwealth University
Richmond, Virginia

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Zelia M. Correa, MD, PhD, is a consultant for Castle Biosciences, Inc.

Jessica Randolph, MD, is an advisory board member of AbbVie Inc*, Advarra, and Genentech, Inc*; and is on the speakers bureau for Apellis Pharmaceuticals Inc.

Katherine Talcott, MD, is an advisory board member of Alimera Sciences, Apellis Pharmaceuticals Inc, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, and Genentech, Inc; is on the speakers bureau for Astellas Pharma Inc, and Genentech, Inc; and is a contracted researcher for Regeneron Pharmaceuticals, Inc, Regenxbio Inc, and Zeiss.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Regeneron Pharmaceuticals, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Regeneron Pharmaceuticals, Inc, or the American Academy of Ophthalmology.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 315

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.